In 2013, Stern et al. treated acute myeloid leukemia (AML), Acute Lymphocytic Leukemia, Hodgkin’s lymphoma (HL), and sarcoma patients with allogeneic NK cells (CD3 depleted and CD56 selected) after a haploidentical HSCT, using the same donor as NK cell source. Here, NCAM1 is linked to Hodgkins lymphoma.